BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/24/2023 1:35:50 PM | Browse: 185 | Download: 352
 |
Received |
|
2022-11-09 03:03 |
|
Peer-Review Started |
|
2022-11-09 03:05 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-11-24 16:07 |
|
Revised |
|
2022-11-30 21:32 |
|
Second Decision |
|
2023-02-03 03:37 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-02-09 02:27 |
|
Articles in Press |
|
2023-02-09 02:27 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-02-10 02:02 |
|
Publish the Manuscript Online |
|
2023-02-24 13:35 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Chun-Ye Zhang, Shuai Liu and Ming Yang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ming Yang, DVM, PhD, Postdoctoral Fellow, Department of Surgery, University of Missouri, Room 2203, NexGen Precision Building, 1030 Hitt Street, Columbia, MO 65211, United States. yangmin@health.missouri.edu |
| Key Words |
Chronic liver disease; Alcoholic liver disease; Non-alcoholic fatty liver disease; Hepatocellular carcinoma; Natural products; Inflammation; Oxidative stress; Treatment; Clinical trials |
| Core Tip |
Chronic liver disease (CLD) is a continuous process that causes a reduction of liver function lasting more than six months. CLD can be subclassified into alcoholic liver disease, non-alcoholic fatty liver disease, chronic viral infection, and autoimmune hepatitis, which can lead to liver fibrosis, cirrhosis, and cancer. Liver inflammation and oxidative stress are commonly associated with the development and progression of CLD. Therefore, anti-inflammatory and antioxidant agents are promising drugs for CLD treatment. Clinical trials are undergoing to evaluate their efficacy and safety. |
| Publish Date |
2023-02-24 13:35 |
| Citation |
Zhang CY, Liu S, Yang M. Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy. World J Hepatol 2023; 15(2): 180-200 |
| URL |
https://www.wjgnet.com/1948-5182/full/v15/i2/180.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v15.i2.180 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
